
Please try another search
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Name | Age | Since | Title |
---|---|---|---|
Alain Carpentier | - | 2010 | Honorary President |
Stephane Piat | 50 | 2016 | CEO & Director |
Mark Slaughter | - | - | Member of the Scientific Committee |
Jean-Luc Lemercier | 66 | 2017 | Independent Director |
Edoardo Gronda | - | - | Member of the Scientific Committee |
Michael Mack | 77 | 2017 | Independent Director |
Gunther Laufer | - | - | Member of the Scientific Committee |
Friedrich-Wilhelm Mohr | - | - | Member of the Scientific Committee |
Pierre Bastid | 70 | 2018 | Independent Chairman |
Paul Mohacsi | - | - | Member of the Scientific Committee |
David Coti | 42 | 2021 | Director |
John B. Hernandez | 58 | 2021 | Independent Director |
Florent Battistella | 64 | 2021 | Independent Director |
Paolo Rampulla | 52 | 2023 | Director |
Marie-Pierre Merle-Beral | 62 | 2023 | Director |
Laurent Kirsch | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review